Website is intended for physicians
Search:

 

Abstract:

Eighteen experimental animals (9 rabbits and 9 mongrel dogs) were used in a feasibility study of heparin and a polymer belonging to polyoxyalkanoates class - homopolymer of в-oxybutyric acid - polyoxybutyrate (POB) to be applied onto the surface of the nitinole self-expanding stent "Alex" ("Komed", Russia) in order to decrease responsiveness of the vascular wall. During a three-month chronic experiment at various terms following implantation, we examined the degree of biocompatibility of the coat-free stents, heparin-treated stents, and those coated with the above polymer. The studies were carried out by means of arteriography, binocular light microscopy, histological examination, electron microscopy; and the study of the ultrastructure of thestented segmentsof the vessels. The experiments carried out on animals showed that: 1. The coating of the stents may positively influence structural alterations in the vascular wall, which improve the conditions of the blood flow along the vessel; 2. Using POB-coated stents is accompanied by lesser intimal hyperplasia, relatively decreased leukocytic infiltration, and development of vasa vasorum; 3. POB may safely be considered the most favourable coating for stents because of minimal structural alterations in the vascular wall. The obtained findings would make it possible to plan future research on polyoxyalkanoatesas modifiers of the histological responseof the vascular wall tissues while implanting stents.

 

       References

1.     Holmes D.RJr., Leon M.B., Moses J.W., Popma J.J., Cutlip D., Fitzgerald P.J., Brown C., Fischell T., Wong SC., Midei M., Snead D., Kuntz R.E.. Analysis of 1-Year Clinical Outcomes in the SIRIUS Trial. A Randomized Trial of a Sirolimus-Eluting Stent Versus a Standard Stent in Patients at High Risk for Coronary Restenosis. Circulation. 2004; 109: 634-640.

2.     Machan L. Drug eluting stents in the infrainguinal circulation. Tech. Vasc. Interv. Radiol. 2004; 7: 28-32.

3.     Tanabe K., Serruys P., Grube E., Smits P.C., Selbach G., van der Gissen W.J., Staberock M., de Feyter P., Muller R., Reger E., Degertekin M., Ligthart J.M.R., Disco C., Backx B., Russell M.ETAXUS III Trial. In-Stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formation. Circulation. 2003; 107: 559-564.

4.     Grube E., Silber S., Hauptmann K.E., Mueller R., Buellesfeld L., Gerckens U., Russell M.E. TAXUS I. Six- and twelve-months results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003; 107: 38-42.

5.     Kerner A., Gruberg L., Kapeliovich L., Grenadier E. Late stent thrombosis after implantation of a sirolimus-eluting stent. Catheter Cardiovasc. Interv. 2003; 60: 505-508.

6.     Jeremias A., Sylvia B., Bridges J., Kirtane A.J, Bigelow B., Pinto D.S., Ho K.K., Cohen D.J., Garcia L.A., Cutlip D.E., Carrozza J.P. Jr. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation. 2004; 109: 1930-1932.

7.     Шишацкая Е.ИМедико-биологические свойства биодеградирующих бактериальных полимеров полиоксиалканоатов для искусственных органов и клеточной трансплантологииДисс. канд. мед. наук 2003; 156.

8.     Протопопов А.В. Разработка и клиническое внедрение метода эндопротезирования сосудов саморасширяющимся нитиноловым стентом (клинико-экспериментальное исследование). Диссдокмеднаук. 2002; 240.

9.     Peck P. Concerns About Subacute Thrombosis and the Sirolimus-Eluting Stents: Hype or Reality? Posted 12.10.2003. Available at:http//www.medscape.com/viewarticle/465210 - 50k.

10.   FDA Public Health Web Notification: Information for Physicians on Sub-acute Thromboses (SAT) and Hypersensitivity Reactions with Use of the Cordis CYPHER™ Coronary Stent. Issuing Date: October 28, 2003. Available at:http: //www.fda.gov/cdrh/safety/cypher.html.

11.   FDA Public Health Web Notification: Updated information for physicians on sub-acute thromboses (SAT) and hypersensitivity reactions with use of the Cordis CYPHER™ sirolimus-eluting coronary stent. Issuing Date: November 25, 2003. Available at: http://www.fda.gov/cdrh/safety/cypher2.pdf.

12.   Babinska A., Markell M.S., Salifu M.O. Enhancement of human platelet aggregation and secretion induced by rapamycin. Nephrol. Dial. Transplant. 1998; 13: 1353-1359.

13.   U.S. Food and Drug Administration, Center for devices and radiological health, Cypher sirolimus-eluting coronary stent on RAPTOR over-the-wire delivery system. Available at:http://www.fda.gov/cdrh/ pdf3/p020026.html.

14.   Lau W.C., Waskell L.A., Watkins P.B. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation. 2003; 107: 32-37.

15.   van der Giessen W.J., van Beusekom H.M., van Hoeten C.D., van Woerens L.J., Verdouw P.D., Serruys P.W. Coronary stenting with polymer-coating and uncoated self-expanding endoprostheses in pigs. Coronary artery disease. 1992; 3: 631-640.

16.   van der Giessen W.J., Slager C.J., van Beusekom H.M., van Ingen Schenau D.S., Huuts R.A., Schuurbiers J.C., de Klein W.J., Serruys P.W Development of a polymer Endovascular prosthesis and its implantation in porcine arteries. J. Interven. Cardiol. 1992; 5: 175-185.

17.   Unverdorben M., Spielberger A., Schywaisky M., Labahn D., Hartwig S., Schneider M., Lootz D., Behrend D., Schmitz K., Degenhardt R., Schaldach M., Vallbracht C. A polyhydroxybutyrate biodegradable stent: preliminary experience in the rabbit. CVIR.2002; 25: 127-132.

18.   Tamai H., Igaki K., Kyo E., Kosuga K., Kawashima A., Matsui S., Komori H.,TsujiT., Motohara S., Uehata H.. Initial and 6-month results of biodegradable poly-L- lactic acid coronary stents in human. Circulation. 2000; 102: 399-404.

ANGIOLOGIA.ru (АНГИОЛОГИЯ.ру) - портал о диагностике и лечении заболеваний сосудистой системы